Phase I randomized double‑blind placebo‑controlled single‑dose safety studies of Bowman‑Birk inhibitor concentrate

Lin,Lilie L.; Mick,Rosemarie; Ware,Jeffrey; Metz,James; Lustig,Robert; Vapiwala,Neha; Rengan,Ramesh; Kennedy,Ann R.

doi:10.3892/ol.2014.1855

Phase I randomized double‑blind placebo‑controlled single‑dose safety studies of Bowman‑Birk inhibitor concentrate

Authors:
- Lilie L. Lin
- Rosemarie Mick
- Jeffrey Ware
- James Metz
- Robert Lustig
- Neha Vapiwala
- Ramesh Rengan
- Ann R. Kennedy
View Affiliations

Affiliations: Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Published online on: February 5, 2014 https://doi.org/10.3892/ol.2014.1855
Pages: 1151-1158

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In previously performed animal studies and Phase I‑II human trials, Bowman‑Birk inhibitor concentrate (BBIC) appeared to be a promising cancer chemopreventive agent. The present study describes the results of two phase I randomized double‑blind placebo‑controlled trials performed in male subjects to assess the safety and toxicity of the original and new formulations of BBIC administered in a single dose as a suspension in orange juice. The dose of BBIC varied from 800‑2,000 chymotrypsin inhibitor (CI) units. The BBI concentration in the serum samples collected from the subjects was analyzed by a dot‑blot analysis procedure using the 5G2 monoclonal antibody, which is specific for reduced BBI. A total of 41 subjects were enrolled, 20 in the initial BBIC study and 21 in the second BBIC study. In these human trials, no clinically relevant changes in hematological or biochemical parameters were observed. Overall, BBIC was found to be well‑tolerated. For these BBIC single‑dose phase I trials, there was no dose‑limiting toxicity for BBIC, even at the highest dose evaluated, and there were no apparent differences between the clinical trial results for the two formulations of BBIC. The bioavailability of BBI in the second clinical trial, which used the new BBIC formulation, was approximately 40 to 43% of the BBI bioavailability reached in the first clinical trial, which used the original BBIC formulation. The observed bioavailability difference was attributed to the different BBIC formulations used in these two clinical trials. These trials demonstrated that BBIC is safe when administered in a single dose of up to 2,000 CI units. Therefore, the results from the two trials indicate that a multi‑dose trial of BBIC may be safely performed with doses of up to 2,000 CI units per day.

View Figures

View References

1	Messina MJ, Persky V, Setchell KD and Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 21:113–131. 1994. View Article : Google Scholar : PubMed/NCBI
2	Kennedy AR: The evidence for soybean products as cancer preventive agents. J Nutr. 125(3 Suppl): 733S–743S. 1995.PubMed/NCBI
3	Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther. 78:167–209. 1998. View Article : Google Scholar : PubMed/NCBI
4	Larionova NI, Gladysheva IP, Tikhonova TV and Kazanskaia NF: Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biokhimiia. 58:1437–1444. 1993.(In Russian). View Article : Google Scholar : PubMed/NCBI
5	Tikhonova TV, Gladysheva IP, Kazanshaya NF and Larionova NI: Inhibition of elastin hydrolysis, catalyzed by human leukocyte elastase and cathepsin G, by the Bowman-Birk type soy inhibitor. Biokhimiia. 59:1739–1745. 1994.(In Russian). View Article : Google Scholar : PubMed/NCBI
6	Gladysheva IP, Larionova NI, Gladyshev DP, Tikhonova TV and Kazanskaia NF: The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biokhimiia. 59:513–518. 1994.(In Russian). View Article : Google Scholar : PubMed/NCBI
7	Ware JH, Wan XS, Rubin H, Schechter NM and Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys. 344:133–138. 1997. View Article : Google Scholar
8	Kennedy AR: Cancer prevention by protease inhibitors. Prev Med. 22:796–811. 1993. View Article : Google Scholar : PubMed/NCBI
9	Kennedy AR: Anticarcinogenic activity of protease inhibitors: Overview. Protease Inhibitors as Cancer Chemopreventive Agents. Troll W and Kennedy AR: 1st edition. Plenum Press; New York: pp. 9–64. 1993, View Article : Google Scholar
10	Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther. 78:167–209. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kennedy AR, Szuhaj BF, Newberne PM and Billings PC: Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer. 19:281–302. 1993. View Article : Google Scholar
12	Kennedy AR: In vitro studies of anticarcinogenic protease inhibitors. Protease Inhibitors as Cancer Chemopreventive Agents. Troll W and Kennedy AR: 1st edition. Plenum Press; New York: pp. 65–91. 1993, View Article : Google Scholar
13	Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE and Meyskens FL Jr: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev. 9:43–47. 2000.PubMed/NCBI
14	Malkowicz SB, McKenna WG, Vaughn DJ, et al: Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate. 48:16–28. 2001. View Article : Google Scholar : PubMed/NCBI
15	Armstrong WB, Kennedy AR, Wan XS, et al: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res. 6:4684–4691. 2000.
16	Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR and Ware JH: Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci. 53:175–180. 2008. View Article : Google Scholar : PubMed/NCBI
17	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
18	Wan XS, Koch CJ, Lord EM, et al: Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor. J Immunol Methods. 180:117–130. 1995. View Article : Google Scholar
19	Furuya Y, Cho S, Ohta S, Sato N, Kotake T and Masai M: High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer. J Urol. 166:2132001. View Article : Google Scholar : PubMed/NCBI
20	Fleseriu M, Lee M, Pineyro MM, et al: Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’. J Neurooncol. 79:41–43. 2006.PubMed/NCBI
21	McCudden CR, Voorhees PM and Hammett-Stabler CA: A case of hook effect in the serum free light chain assay using the Olympus AU400e. Clin Biochem. 42:121–124. 2009. View Article : Google Scholar : PubMed/NCBI
22	Meyskens FL Jr, Armstrong WB, Wan XS, et al: Bowman-Birk inhibitor concentrate (BBIC) affects oral leukoplakia lesion size, neu protein levels and proteolytic activity in buccal mucosal cells. Proc. Am. Assoc. Cancer Res. 40:Abstract #2855. 1999.
23	Wan XS, Meyskens FL Jr, Armstrong WB, Taylor TH and Kennedy AR: Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomark Prev. 8:601–608. 1999.
24	Malkowicz SB, Broderick GA, Zoltick B, et al: Phase I study of oral Bowman-Birk inhibitor concentrate (BBIC), a soy protein, on patients with lower urinary tract symptoms. J Urol. 161:2281999. View Article : Google Scholar
25	Billings PC, Brandon DL and Habres JM: Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer. 27:903–908. 1991. View Article : Google Scholar : PubMed/NCBI
26	Billings PC, St Clair WH, Maki PA and Kennedy AR: Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett. 62:191–197. 1992. View Article : Google Scholar
27	Yavelow J, Finlay TH, Kennedy AR and Troll W: Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res. 43(5 Suppl): 2454s–2459s. 1983.PubMed/NCBI
28	Brandon DL, Bates AH and Friedman M: Monoclonal antibody-based enzyme immunoassay of the Bowman-Birk protease inhibitor of soybeans. J Agric Food Chem. 37:1192–1196. 1989. View Article : Google Scholar
29	Brandon DL, Bates AH and Friedman M: ELISA analysis of soybean trypsin inhibitors in processed foods. Adv Exp Med Biol. 289:321–337. 1991. View Article : Google Scholar : PubMed/NCBI
30	Brandon DL: Antigenicity of soybean protease inhibitors. Protease inhibitors as Cancer Chemopreventive agents. Troll W and Kennedy AR: 1st edition. Plenum Press; New York: pp. 107–129. 1993, View Article : Google Scholar
31	Wan XS, Lu LJ, Anderson KE, Ware JH and Kennedy AR: Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. Cancer Epidemiol Biomark Prev. 9:741–747. 2000.PubMed/NCBI
32	Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr. 68(6 Suppl): 1406S–1412S. 1998.PubMed/NCBI